How 48 doctors think about active surveillance

Many patients, prostate cancer advocates, and prostate cancer educators may be interested in a recent article exploring how physicians who manage prostate cancer regularly think about active surveillance (AS) and how to discuss this with their patients. … READ MORE …

SBRT has equivalent toxicity with 5 treatments and 12 treatments: an update

We first reported data from the results of the RTOG 0938 trial in January 2016 when they were presented at the Genitourinary Cancers Symposium in that year. These results have now been formally published, and there are some changes to the data on publication, so Allen Edel has provided an update. … READ MORE …

Improving prognostic guidance for men with advanced and progressive forms of prostate cancer

A recent report on Renal & Urology News discusses long-term follow-up data from a cohort of > 2,600 prostate cancer patients who were followed from diagnosis for up to 10 years until their deaths. … READ MORE …

Active surveillance in Oz: a situation report

An interesting article published a couple of week’s ago in the Medical Journal of Australia reports on “real world issues” related to the implementation of active surveillance (AS) in Oz. … READ MORE …

Is it or ain’t it “really” cancer?

In a new article in the Journal of Urology, researchers at Johns Hopkins Medical Center in Baltimore have again expressed their opinion that it would be inappropriate to rename low-risk Gleason 6 disease as something other than “cancer”. … READ MORE …

“I’m not having another biopsy after the last one!”

It will come as no particular surprise that men who have had complications after a prior biopsy tend to be less enthusiastic when it is suggested that they need another one. However, … … READ MORE …

What is “Prostac” and where can you get it?

Someone asked the sitemaster yesterday about a new test for risk of prostate cancer called Prostac® and where he could access this. … READ MORE …